|
|
||||||||





* Center for Global Health and Diseases, Case Western Reserve University, Cleveland, OH 44106;
Kenya Medical Research Institute, Nairobi, Kenya;
Division of Vector Borne Diseases, Nairobi, Kenya; and
Department of Veterans Affairs Medical Center, Cleveland, OH 44106
| Abstract |
|---|
|
|
|---|
secretion were highly concordant. However, IL-10 and IL-13 secretion were not correlated. Importantly, the fine specificity of lymphocyte proliferation and cytokine secretion in cord and adult blood mononuclear cells was similar. Cord blood cells obtained from malaria-infected pregnant women were 4-fold more likely to acquire a peptide-specific immune response. We conclude that the fetal malaria response functions in a fully adaptive manner and that this response may serve to help protect the infant from severe malaria during infancy. | Introduction |
|---|
|
|
|---|
Despite this interest, CBMC to various Ags have been poorly characterized. It is known that CD4+ and/or CD8+ T cells are stimulated (7), but whether these represent classical CD45RO+ memory T cells eliciting a recall response or nonspecific activation of naive T cells is not well-understood. Indeed, memory function of low numbers of CD45RO+ T cells in the fetal circulation remains undetermined. Recent characterization of CBMC to environmental allergens indicated that a significant component of T cell reactivity was not mediated by memory T cells, but rather via a default response of recent thymic emigrants, inducing a transient cellular immune response in the absence of conventional T cell memory (8, 9).
A defining property of fetal TCR is the shorter size of their CDR3 regions in comparison to CDR3s in adults (10). The CDR3 (11) is encoded by nucleotide sequences derived from the junctions of V, D, and J segments and flanking regions, forming part of the Ag-binding groove of the TCR; it is a key site of fine Ag recognition (12). Short fetal CDR3 regions may result in flat Ag-binding sites (13). This may explain the frequent presence of low-affinity polyreactive specificities in naive frequent thymic emigrants in the fetal immune system (14, 15). This low-affinity response is illustrated in T cell epitope mapping of OVA, a common food allergen, in cord compared with adult blood. CBMC demonstrate broadly reactive responses to multiple OVA peptides that are absent in adults (15), suggesting fetal lymphocytes lack of fine antigenic specificity to certain Ags.
To examine further whether fetal lymphocytes can acquire fine specificity of immune response to a different Ag, we examined the recall responses to peptides corresponding to the malaria blood-stage Ag merozoite surface protein 1 (MSP1). In contrast to inhalant or food allergens, malaria offers a good paradigm to study fetal immune responses to exogenous Ags. Malaria infects erythrocytes, releasing large quantities of Ag intravascularly, which can cross the placenta to directly expose the fetus, either through soluble Ag (16, 17) or infected erythrocytes during pregnancy (17, 18, 19). We and others have shown that 20–70% of CBMC collected from newborns of women living in malaria holoendemic areas of Africa have recall responses to MSP1 and/or other malaria blood-stage Ags (5, 6, 20). Recall responses to blood-stage Ags in CBMC occur more frequently in newborns of primi- and secundigravid women, who are at increased risk of parasite sequestration in the placenta during pregnancy, and therefore more likely to expose their fetus to soluble malaria Ags (17, 19). No recall responses to peptides corresponding to malaria pre-erythrocytic-stage Ags are noted with CBMC, which occur in very low concentrations and are primarily found in hepatocytes and not intravascularly (5, 6), suggesting a high level of specificity to Ags expressed during different stages of the malaria parasite life cycle. In contrast, recall responses to pre-erythrocytic-stage peptides occur in young children and adults (21, 22). This study examines the hypothesis that the fetus can acquire a similar fine specificity of the adaptive immune responses to MSP1 compared with adults.
Plasmodium falciparum MSP1 is a 195-kDa GPI-anchored protein on the merozoite surface, representing the most abundant merozoite surface protein (23). It undergoes a series of proteolytic cleavages during merozoite invasion of erythrocytes (23). The final cleavage of the C-terminal 42-kDa portion of MSP1 releases a soluble 33-kDa fragment (24), while the 19-kDa fragment is retained on the merozoite surface and is carried into the erythrocyte during erythrocyte invasion (25). T cell responses are primarily directed to the 33-kDa fragment (MSP133) whereas Ab responses are primarily directed to the 19-kDa fragment (MSP119; Ref. 26). MSP133 is highly polymorphic and forms two distinct allelic families, referred to as the MAD20 allele (3D7 strain) or the Wellcome or K1 allele (or FVO parasite strain). These alleles have 51% amino acid identity (27). Previous studies have examined PBMC recall responses from individuals living in a malaria endemic area to several peptides corresponding to predicted T cell epitopes for both MSP133 and MSP119 (28, 29). No published studies, however, have demonstrated a systematic mapping of T cell epitopes for MSP133 or whether these epitopes differ between the two dominant allelic families. Moreover, no studies have shown detailed T epitope mapping of an immunogenic molecule in cord blood. The current study examines 58 peptides that span both MAD20 and K1 alleles of MSP133, constructed as 18-mer peptides overlapping by nine amino acids, with respect to proliferation and cytokine responses by CBMC from newborns and PBMC from adults residing in holoendemic area for P. falciparum in Kenya.
| Materials and Methods |
|---|
|
|
|---|
CBMC were prepared from umbilical cord blood using previously described protocols (5, 30) from 48 newborns of pregnant women who delivered at the Msambweni District Hospital (Coast Province, Kenya). Intervillous placental and maternal peripheral blood was collected to determine the presence of malaria at delivery. Impression smears from placental tissues were prepared as previously described (5, 19, 20). Peripheral venous blood was collected from three adult men who had been diagnosed with malaria and successfully treated within a month of blood collection. PBMC preparations used a previously described protocol (5, 30). CBMC representing negative controls were prepared from healthy North American newborns vaginally delivered at University Hospitals of Cleveland (n = 10; Cleveland, OH). Ethical approval was obtained from the Human Investigations Institutional Review Boards of University Hospitals of Cleveland and the Kenya Medical Research Institute in Nairobi.
Determination of malaria infection status and genotyping malaria isolates
For blood smear diagnosis, thick and thin films were stained with 4% Giemsa and examined microscopically for asexual P. falciparum under x100 oil immersion fields to determine parasitemia levels. DNA was extracted from 200 µl of whole blood using individual spin blood kits (Qiagen). A total of 2.5 µl of DNA was used for amplification of the multicopy 18S (small subunit (ssu)) ribosomal RNA genes (ssu rRNA) of P. falciparum by real-time quantitative PCR as described previously. PCR was performed using a quantitative thermocycler (GeneAmp 5700 Sequence Detector; ABI Research). Each run included no template DNA (negative control) and serial log-fold dilutions of plasmid containing the ssu rRNA genes (GenBank AF145334) (positive control).
Peripheral or intervillous blood that was positive by blood smear or PCR was then genotyped for the 33-kDa region of MSP1. PCR primers were chosen to distinguish between the MAD20 and K1 dimorphic variants, allowing for the detection of mixed or polyclonal infections to generate a product of
500 bp. MAD20 primers for amplicon "M15" are: 5'-CCATTTTTGGAGAATCCGAAG-3' (aa 1329–1336) and 5'-TTCGTCTGTTTTTGCTGGTG-3' (aa 1504–1510), while "M16" primers are 5'-AAGGTTTTAGCGAAATATAAGGATGA-3' (aa 1475–1484) and 5'-TTCTTCTCTTTCATCTAAATGTCTGAA-3' (aa 1661–1669). K1 primers are as follows: amplicon "K15" 5'-TTGGAGAATCCGAAGAAGATT-3' (aa 1332–1338) and 5'-TTTCACCTTGTTTGTCGTTGA-3' (aa 1489–1515) and "K16" 5'-TTCAATAGATACGGATATAAATTTTGC-3' (aa 1556–1564) and 5'-ACATTCTTCTCTTTCATCTAAATGTCT-3' (aa 1650–1658). The PCR was conducted in a 21-µl reaction volume using 10.84 µl of sterile water, 1 µl of 2.5 mM dNTPs, 2 µl of 10x buffer, 2 µl of 25 mM MgCl2, and 0.16 µl of PE AmpliTaq Gold polymerase (5 U/µl), with 2 µl of forward and reverse primers (2.5 µM). The cycling conditions included initial denaturation at 94°C for 4 min, 45 cycles of denaturation for 1 min 45 s at 94°C, extension for 1 min at 63°C. This is followed by 1 min annealing at 72°C and a final extension for 10 min at 72°C. Three microliters of the PCR product was run out on 1% agarose gel via electrophoresis in 1x Tris-acetate-EDTA buffer. Band visualization was used on CyberGold. Only samples with bands in both block 15 and block 16 for a particular allele are reported as positive.
Peptides, recombinant proteins, and mitogens
Peptides were synthesized by using F-moc biochemistry by Sigma-Genosys. Peptides were 70–80% pure and used without further purification. Thirty 18-mer peptides overlapping by nine amino acids were prepared; these peptides spanned MSP133 based on the P. falciparum MAD20 allele (GenBank sequence no. Z35327.1; Fig. 1 designated as M28–57). Similarly, 28 18-mer peptides overlapping by nine amino acids were prepared corresponding to the P. falciparum the Wellcome or K1 allele (GenBank sequence no. X03371.1, Fig. 1 designated at K26–53). Note two additional peptides were synthesized for the MAD20 allele because of the 20-aa insertion for this allele. Lyophilized peptides were reconstituted in 20% (w/v) DMSO and resuspended in PBS. A working concentration of 100 µg/ml in complete RPMI 1640 (10% human AB serum) was prepared from stock (1 mg/ml) solutions before addition to cultures. rMSP142 corresponding to both MAD20 and K1 alleles was provided by Drs. C. Long, S. Singh, and D. Narum (Malaria Vaccine Development Unit (National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD)). PMA plus ionomycin (Calbiochem) and PHA (Sigma-Aldrich) were used in parallel cultures for positive mitogen controls. The concentration of endotoxin in preparations used for evaluation of lymphocyte responses was <0.5 ng/ml, which is 5- to 50-fold less than that required for stimulation of cytokine production by human lymphocytes. Only preparations that responded to the mitogen are reported. Media alone (negative control), 10 µg/ml MAD20 and K1 peptides, 5 µg/ml MSP142, and PMA (50 pg/ml) plus ionomycin (1 µg/ml) or PHA (1 µg/ml) were added to wells after optimal concentrations were determined in pilot experiments in CBMC and PBMC for lymphocyte proliferation and ELISPOT experiments. Of note, higher concentrations of MSP142 (e.g., 10 and 20 µg/ml) did not induce a greater frequency of MSP142-specific responses in pilot studies or prior investigations (5, 20), which is why the 5 µg/ml was used in the current experiments.
|
A total of 4 x 105 CBMC or PBMC in 200 µl of culture medium was added to each well of a round-bottom 96-well plate (Costar) in triplicate. Cultures were incubated at 37°C in 5% CO2 for 5 days, labeled with 1µCi [3H] thymidine (DuPont NEN Research Products) for 14 h then harvested and radioactivity incorporation was determined using a Matrix 96 beta counter (Packard Instrument). The mean cpm of each set of triplicate wells was calculated, and the simulation index (SI) was determined as the mean cpm of peptide-stimulated culture divided by the mean cpm of unstimulated cultures. A cutoff value of SI of >2.0 was considered positive based on proliferation of the same peptide preparations in CBMC preparations from 10 newborns born in Ohio, whose mothers had never been exposed to malaria in responses. Among these unexposed CBMC SI ranged from 0.7 to 1.9, mean = 0.97, SD = 0.36, n = 580 (e.g., 58 peptides in 10 CBMC samples). Thus, a mean + 3 SD was equal to 2.05 which we rounded to 2.0 as the cutoff.
ELISPOT and ELISA for cytokine production
IFN-
ELISPOT was performed as described (5). Briefly, ELISPOT plates (Millipore) were coated with capture Abs in sterile PBS overnight at 4°C and blocked with complete RPMI 1640 with 10% pooled human AB serum. Plates were then washed three times with sterile PBS. To measure the frequency of Ag-specific IFN-
-secreting cells, 4 x 105 CBMC were added to each well in 200 µl of medium in triplicate and were incubated at 37°C in 5% CO2 for 72 h. Fewer CBMC were added to each well (1 x 104) to measure mitogen-driven cytokine production. A positive response was scored when one of the following conditions was met: 1) an average of >4 IFN-
-secreting cells in response to any one of the peptides or rMSP142, when no IFN-
-secreting cells were present in negative control wells (medium alone); or 2) in cases where IFN-
-secreting cells were observed in negative control wells, the number of spots generated by Ag-driven CBMC was at least 2-fold greater. Malaria Ag-driven, IFN-
-secreting cells were also screened in CBMC from 10 healthy North American newborns or in PBMC from 10 malaria-naive adults. None of the peptides or rMSP142 induced secretion of more than two spots if there were no spontaneous IFN-
production (only observed in two normal CBMC from nonendemic area) and for the two with spontaneous IFN-
secretion peptides induced never exceeded a 1.6-fold increase above background for any peptides.
Quantification of IL-2, IL-4, IFN-
, IL-10, and IL-13 by ELISA was performed on culture supernatants collected at 72 h. Results were expressed in picograms per milliliter by interpolation from standard curves based on recombinant lymphokines (31). Ab pairs for cytokine capture and detection (all biotinylated) were used as previously described (20). A positive response was scored when the following two criteria were fulfilled: 1) a net value for Ag-stimulated cells that was at least 2-fold greater than that of parallel cultures containing medium alone and 2) responses to three or more MSP133 peptides. If cytokine production was not detectable in the negative control cultures, then >40 pg/ml cytokine was considered to be a positive response.
Statistics
The significance of differences between groups was evaluated using the Student t test, and relationships between variables were examined by simple linear regression. Comparisons of the proportions of responders in various groups of donors were evaluated by
2 analysis using Fischers exact test.
| Results |
|---|
|
|
|---|
To identify dominant epitopes, Fig. 2 shows the pattern of lymphocyte proliferation by CBMC (n = 48) to 18-mer peptides spanning the sequence for both the MSP133 MAD20 and K1 alleles. A positive response had a stimulation index of >2. Peptides that stimulated a positive response in the greatest proportion of individuals tended to have higher SI (Fig. 2). Fig. 3 shows peptide-driven IFN-
secretion by a subset of CBMC (n = 23) measured by ELISPOT. Overall, peptides that induced lymphocyte proliferation also stimulated IFN-
. MAD20 peptides 41–43 stimulated the strongest lymphocytes responses in the greatest proportion of individuals indicating the presence of a dominant T cell epitope in this region of the molecule. Additionally, K1 peptides 29–31 and 48–50 stimulated lymphocytes responses in the greatest proportion of individuals indicating that these regions of the molecule also contain strong T cell epitopes. T cell epitopes were distinct and nonoverlapping between the two alleles (Figs. 1–3).
|
|
production by ELISPOT. A cord blood sample was considered to have positive recall responses to MSP133 if there was significant lymphocyte proliferation and/or ELISPOT response to more than or equal to three peptides. Based on this definition, 25 of 48 (52%) CBMC responded to MSP133 based on proliferation and 14 of 23 (61%) of CBMC responded to MSP133 as measured by IFN-
ELISPOT. Of the 14 subjects with significant IFN-
responses to more than or equal to three peptides, 11 also had a significant response as measured by lymphocyte proliferation whereas only 2 of 9 non-IFN-
responders had significant responses by lymphocyte proliferation. Thus, there was significant correlation between lymphocyte proliferation and ELISPOT results (
2, p = 0.01). CBMC responses could be allele specific. Seven CBMC samples responded only to peptides corresponding to the dominant MAD20 T cell epitopes and three CBMC only to peptides corresponding to the dominant K1 T cell epitopes.
|
secretion by ELISPOT (data not shown).
To evaluate other cytokine production, their release was measured in supernatants from the same cultures used for lymphocyte proliferation at 96 h, before the addition of [3H]thymidine. Little appreciable peptide-induced IL-2 or IL-4 was detected in cultures. IFN-
production measured by ELISA paralleled that observed for the ELISPOT assay, however, with a lower sensitivity (data not shown). By contrast, net peptide-induced IL-10 (150–1268 pg/ml) and IL-13 (130–1220 pg/ml) was detected from 12 to 20% of CBMCs, often to peptides that did not induce lymphocyte proliferation or IFN-
production (Fig. 5).
|
We have previously observed that peptides corresponding to previously described T cell epitopes from malaria blood-stage Ags stimulate lymphocyte responses in a greater proportion of CBMC samples compared with a recombinant malaria blood-stage protein tested in the same sample (5, 19, 20). These studies, however, did not directly compare peptides derived from sequences contained within the recombinant protein. To examine this relationship further, a subset of CBMC were also stimulated with rMSP142 corresponding to the MAD20 allele. MSP142 includes the full sequence of MSP133. As shown in Table I, a significantly greater proportion of CBMC samples responded to multiple peptides than to rMSP142 (see Fig. 4). Positive lymphocyte proliferation responses to rMSP142 were 2.1 and 2.2 and frequency of IFN-
-secreting cells to rMSP142 was 85, 147, and 3119 spots per 4 x 105 PBMC. By contrast, all three adult PBMC generated significant lymphocyte proliferation and IFN-
release to both peptides and rMSP142 (data not shown). Similar results were observed with the K1 allele, although the overall number of responders was lower (data not shown). This suggests a possible defect in Ag processing and/or presentation by CBMC.
|
Primi- and secundigravid women have increased frequency of malaria infection and MSP133 peptide-specific lymphocyte proliferation and IFN-
release by CBMC compared with multigravid women
Lymphocyte priming in the fetus is likely to occur by transplacental transfer of malaria Ags or infected erythrocytes during gestation, and not by nonspecific activation of lymphocytes. Therefore, fetal priming should be restricted to women infected with malaria during pregnancy. The presence of malaria in women at delivery was assessed by examining maternal peripheral and intervillous placental blood for the presence of malaria parasites. Because mothers may have been infected with malaria earlier during gestation, but not at the time of delivery, parity was also used a surrogate for prenatal exposure to malaria. Primi/secundigravid women are more susceptible to malaria during pregnancy compared with multigravid women (19). Table II shows that primi/secundigravid women in the study were
4-fold more likely to be malaria infected at delivery, and
3-fold more likely to show a positive lymphocyte proliferation and/or IFN-
response to MSP133 peptides compared with multigravid women. Additionally, the portion of CBMC samples that show positive proliferative responses to more than or equal to three peptides was compared between malaria-infected women and those without detectable malaria at the time of delivery. CBMC from 9 of 15 (60%) malaria-infected women had significant proliferative responses compared with significant proliferative responses in 14 CBMC born to 33 (42%) women uninfected at delivery (p = 0.2, by
2 analysis).
|
| Discussion |
|---|
|
|
|---|
The magnitude of proliferation and IFN-
responses to the three dominant peptides among positive responders was generally low and never reached a stimulation index of >6 (Fig. 2) and mean number of peptide-induced IFN-
cells of
60 cells per 4 x 105 CBMC (Fig. 3). The relatively low response in cord blood likely represent recent priming and/or strong immune modulation such as by T regulatory cells (33, 34).
The dominant T cell epitopes identified in this study both confirm and contradict past studies. Prior studies selected T cell epitopes of MSP133 in humans based on computer algorithms (28, 29), but did not systematically map T cell epitopes as performed in this study. Udhayakumar et al. (28) tested nine peptides, ranging from 14 to 20 aa for MSP133 for the MAD20 allele. One peptide that stimulated the greatest proportion of adult responders corresponded exactly to the dominant MAD20 peptide observed in our study (GISYYEKVLAKYKDDLE). Only one other study examined peptides corresponding to MSP133 in humans (29). This study selected three peptides corresponding to MAD20 and three of the K1 allele of MSP133 using a different computer algorithm than the study by Udhayakumar et al. (28) Overall, they observed a lower frequency of lymphocyte responses to their peptides compared with our study, even though the malaria endemicity was similar between study populations. None of the peptides corresponded to dominant T cell epitopes identified in our study. This suggests that their peptides, although immunogenic, may not represent dominant T cell epitopes. They did, however, show clear allele-specific differences in some donors, as observed in our study. Overall, our findings are consistent with earlier studies, but they emphasize the importance of a systematic mapping of T cell epitopes because algorithms used previously did not consistently identify the dominant T cell epitopes.
The presence of CBMC responses to MSP133 peptides was greater in primigravid and secundigravid compared with multigravid women, consistent with exposure to malaria in utero. Parity is a useful surrogate for malaria infection because primi- and secundigravid women are at significantly higher risk of malaria during pregnancy (35) and Table II and thus more likely to have fetal exposure to malaria Ags. This observation is consistent with the notion that recall responses to MSP133 peptides are specific and directed to fetal memory T cells previously exposed to malaria Ags, rather than due to nonspecific activation of naive T cells. Although there was trend toward greater CBMC responses to MSP1 among malaria-infected women compared with uninfected women at delivery, this difference was not significant. This is not surprising because some malaria infections may have been acquired shortly before or at delivery and therefore would not have sufficient time to prime the fetus.
Even though MAD20 was the dominant circulating genotype of MSP133 in the community and in the maternal infections screened in this study, the proportion of CBMCs and PBMCs samples responding to peptides from one or both variants was similar. A prior study also found a similar discordance between the frequency of responses to allele-specific peptides and the epidemiological distribution of different MSP1 alleles (29). The reasons for this discordance are unclear, however, there are several plausible explanations. First, it is possible that pregnant women in the current study could have been infected with parasites expressing the K1 allele earlier during pregnancy sufficient to prime the fetus and to generate T cell memory. Second, the K1 allele has two dominant T cell epitopes, whereas MAD20 has just one and is thus more likely to be HLA class II restricted. Third, this allelic dimorphism may have evolved independent of parasite strain frequency-dependent selection, such as by allelic altered peptide ligands to interfere with T cell priming (36).
Recent human vaccine studies with rMSP142 have shown good immunogenicity and safety, but failed to demonstrate protection in phase 2 trials (Refs. 37 and 38 and E. Angov, et al. Abstract no. 12, 2007 American Society for Tropical Medicine and Hygiene Meeting), indicating that a better vaccine formulation is required. Based on findings from the current study, the vaccine may be modified, for example, to include repeats of the different variants of the dominant T cell epitopes of MSP133 that could enhance protective Ab responses, increase Ab-independent protection to MSP133 as has been observed with murine malaria (39), and improve strain-transcending immunity. It is possible to immunize with separate MSP133 and MSP119 fragments that would provide the necessary T cell help and also produce Abs targeting MSP133 that could enhance protective anti-MSP119 Ab responses (40).
Circulating neonatal T cells are fundamentally different from those of naive adult T cells that could potentially affect the response to exogenous Ags. Not surprisingly, fetal T cells have many characteristics of recent thymic emigrants including 1) high concentrations of TCR excision circles which are episomal DNA by-products of a TCR
-chain rearrangement that are not replicating but are diluted during cell division; 2) a high proportion of cells in cycle; and 3) increased propensity to undergo apoptosis (41). Together, this indicates high cell turnover (42), which is thought to expand TCR diversity, establish the T cell repertoire, and populate peripheral lymphatic tissues (41, 43). As a consequence, many naive T cells may have low-affinity TCRs and reduced threshold for T cell activation and expansion without production of conventional memory T cells (8, 9). Therefore, the presence and pattern of cytokine responses to Ags in cord blood might have little relevance to development of immune responses to the same Ags later in childhood. The current study challenges this proposition by showing CBMC demonstrated a distinct pattern of lymphocyte responses to MSP133 peptides, showing clearly definable dominant T cell epitopes. Most peptides, however, failed to stimulate any response by CBMC, disproving nonspecific activation of lymphocytes. Moreover, the dominant T cell epitopes were distinct for the two different allelic forms of PfMSP133 indicating a clear specificity of cord blood T cell responses. These dominant T cell epitopes were identical with those identified in PBMC from adults known to be previously infected or exposed to P. falciparum from the same geographical area. Thus, the fetus is capable of generating a repertoire of peptide-specific T cells similar to adult responses.
How the fetus is exposed to Ags may account for the difference in CBMC responses vs environmental allergens. Inhalant or food Ags/allergens are likely to have much lower systemic levels compared with malaria and only certain Ags may cross the placenta. By contrast, malaria-infected erythrocytes can pass transplacentally, exposing the fetus to a wide variety of molecules including those that activate innate immune responses. A notable molecule is GPI which anchors MSP1 and other membrane-associated molecules to the plasma membrane of intact parasites (44) and is a potent TLR agonist (45). Because APCs in the fetus show diminished responses to TLR ligands and deliver less costimulatory signals compared with adult APC, altered T cell responses in the fetus may occur (46). However, if the fetus is exposed to molecules that stimulate innate immunity, lymphocytes may acquire functional characteristics similar to those of adult lymphocytes. Supporting this explanation is detection of functionally normal cord blood Ag-specific CD8+ T cells in response to congenital infections with CMV and T. cruzi (1, 2) and Ag-specific neonatal CD4+ T cell to intravascular helminthes and mycobacterial Ags (30, 47). Thus, an immune response in the fetus is more likely to resemble that of an adult if the fetus is exposed to sufficient quantities of Ag in the context of stimulation of innate immunity, thereby overriding functional defects in neonatal APCs.
Functional defects of neonatal APCs do persist as suggested by the observation in the current study that CBMC are 3-fold more likely to respond to peptides compared with rMSP142. By contrast, adult PBMC responded equivalently to peptides and rMSP142. Processing of MSP142 may be particularly difficult because the C-terminal region is cysteine-rich with two epidermal growth factor-like motifs, each with multiple disulfide bonds (26). We have previously observed a greater proportion of individuals responding to malaria peptides compared with rAg (5, 20); however, we have never directly compared responses to the same rAg and peptides as was done here. This suggests that detection of recall responses to specific Ags in cord blood may be made more sensitive by using peptides. An alternative explanation may account for the difference in response to rMSP142 and peptides. The fetus may have been preferentially exposed to MSP133 compared with the full-length MSP142 because secondary processing of MSP142 leads to release of MSP133 in serum (24). These fragments may be preferentially transported transplacentally, whereas the MSP142 fragment would more likely result from the less frequent fetal exposure to the merozoite or infected erythrocytes (19).
Peptide-induced IL-10 and IL-13 production by CBMC failed to correlate with that observed for lymphocyte proliferation and IFN-
release. The proportion of individuals producing these cytokines was also >2-fold lower than that observed for lymphocyte proliferation and/or IFN-
release. There are several possible explanations for this disparity. First, certain peptides recognize low-affinity receptors on naive, recent thymic emigrants and this low receptor engagement stimulates the release of certain cytokines rather than lymphocyte proliferation. Nonspecific binding to naive T cells is unlikely because addition of these same peptides to CBMC obtained from North American newborns failed to stimulate any detectable cytokine response. Second, partial engagement of low-affinity TCRs on previously activated T cells could generate a different signal leading to cytokine production rather than lymphocyte proliferation (48). This is in contrast to peptides with higher affinity binding to TCR which stimulate lymphocyte proliferation and IFN-
production (48). Third, certain peptides of MSP133 stimulate T cells to develop into Th1-type phenotypes whereas other MSP133 peptides induce differentiation of T cells into alternative phenotypes that secrete other cytokines, but weakly proliferate and release little IFN-
. Ultimately, we can better differentiate these pathways by looking at the T cell phenotype using various cell surface markers, e.g., CD3+, CD4+, CD8+, and CD45 isoforms and by examining cytokine production using flow cytometry and proliferation by CSFE labeling.
In conclusion, these results support a model in which human neonates can mount a spectrum of immune responses to exogenous Ags, ranging from nonspecific activation to a fully mature immune response. This flexibility of responsiveness may have arisen to protect the fetus from harmful effects due to excessive inflammatory responses and yet enable the fetus to develop adaptive immune responses against potentially life-threatening pathogens. The adaptive responses to malaria Ags in the fetus may play functional roles in generating both immunoregulatory and immunoprotective states against severe disease during infancy and early childhood.
| Acknowledgments |
|---|
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported by Health and Human Services Grant AI064687 and by the Veterans Affairs Research Service. ![]()
2 Address correspondence and reprint requests to Drs. Indu Malhotra and Christopher L. King, Case Western Reserve University, Wolstein Research Center Room 4132, 2103 Cornell Road, Cleveland, OH 44106. E-mail addresses: ijm{at}case.edu and cxk21{at}case.edu ![]()
3 Abbreviations used in this paper: CBMC, cord blood mononuclear cell; MSP1, merozoite surface protein 1; ssu, small subunit; SI, stimulation index. ![]()
Received for publication October 18, 2007. Accepted for publication December 20, 2007.
| References |
|---|
|
|
|---|
β T cell receptor structure at 2.5 A and its orientation in the TCR-MHC complex. Science 274: 209-219.
and diminished interleukin-10 production. J. Infect. Dis. 184: 1176-1182. [Medline]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |